Bibliometric analysis of N6-methyladenosine in cancer: landscapes, highlights and trending topics | Zendy

Haotian Jiang | Zendy; Yuan Li | Zendy; Yinghui Liu | Zendy; Weiguo Dong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bibliometric analysis of N6-methyladenosine in cancer: landscapes, highlights and trending topics

Author(s) -

Haotian Jiang,

Yuan Li,

Yinghui Liu,

Weiguo Dong

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2022-0086

Subject(s) - medicine , web of science , bibliometrics , n6 methyladenosine , china , cancer , oncology , bioinformatics , library science , meta analysis , gene , geography , biology , genetics , archaeology , computer science , methyltransferase , methylation

Background: N6-methyladenosine (m 6 A) is crucial in cancer and is being intensively studied. Aim: This bibliometric analysis seeks a broad picture of the role of m 6 A in cancer to guide and broaden future research. Methods: Publications were retrieved from Web of Science Core Collection and PubMed from 2000 to 2021, with keywords ‘m 6 A’ and ‘cancer’, and analyzed in biblioshiny and VOSviewer. Results: A total of 1013 documents were included, and China and the USA were the top countries with close collaboration. Mechanisms and predictive biomarkers of m 6 A regulator genes were highlighted. Cross-integration of m 6 A and other research hot spots, including ‘immunotherapy’, ‘hypoxia' and ‘polymorphism’, were frontiers of m 6 A in cancer. Conclusion: This bibliometric study offered an updated perspective on m 6 A in cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research